Trial | Design | Time | Region | Primary | Treatment | Median follow-up | Sample | Median | Histology(%) | Consolidation | Radiotherapy | Radiotherapy |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Range | Endpoint | (months) | Size | Age | (SCC/non-SCC) | Chemotherapy | Dose(Gy) | Technology | ||||
Liang/2017 [4] | III | 2007–2011 | China | OS | EP | 73 | 95 | 59 | 68.4/31.6 | 50.5% | 60–66 | 3D |
PC | 96 | 57 | 64.6/35.4 | 35.4% | ||||||||
Wang/2012 [5] | II | 2004–2007 | China | OS | EP | 46 | 33 | 55.4 | 69.7/30.3 | 75.8% | 60–66 | 3D |
PC | 32 | 60.9 | 62.5/37.5 | 59.4% | ||||||||
Shuayb/2018 [6] | II | NR | Bangladesh | NR | EP | NR | 30 | NR | NR | NR | 45 | NR |
PC | 30 | NR | NR | NR | ||||||||
Bradley/2015 [7] | III | 2007–2011 | USA | OS | PC-Cet | 21 | 237 | 64 | 43/57 | 67% | 60–74 | 3D |
PC | 23 | 228 | 64 | 46/54 | 67% | |||||||
Sugawara/2013 [8] | II | 2006–2009 | Japan | ORR | UP | 20 | 35 | 62 | 42.9/57.1 | 60% | 60 | 2D − +3D |
NP | 31 | 61 | 35.5/64.5 | 58.1% | ||||||||
Zhao/2016 [9] | III | 2008–2012 | China | OS | NP | 29 | 48 | 57.4 | 67/33 | 88% | 60.6–74.4 | 3D |
PP | 52 | 60.3 | 60/40 | 87% | ||||||||
Sasaki T/2018 [10] | II | 2009–2012 | Japan | OS | SP | NR | 54 | 60 | 31.5/68.5 | 59.3% | 60 | 3D |
NP | 54 | 62 | 31.5/68.5 | 44.4% | ||||||||
Curran Jr./2011 [11] | III | 1994–1998 | USA | OS | NP | 132 | 195 | 60 | 38/62 | NR | 60 | NR |
EP | 187 | 63 | 37/63 | NR | ||||||||
Oh/2013 [12] | III | 2005–2007 | Korea | ORR | PC | Over 36 | 33 | 64 | 72.7/27.3 | 63.6% | 60–66 | 3D |
DP | 29 | 61.5 | 69/31 | 65.5% | ||||||||
GP | 31 | 64 | 64.5/35.5 | 64.5% | ||||||||
Segawa/2010 [13] | III | 2000–2005 | Japan | OS | MVP | NR | 101 | NR | 52.5/37.5 | NR | 60 | 2D |
DP | 99 | NR | 44.4/55.6 | NR | ||||||||
Takiguchi/2018 [14] | II | 2011–2014 | Japan | OS | SP | 48 | 53 | NR | 26.4/73.6 | NR | 60 | NR |
DP | 53 | NR | 20.8/79.2 | NR | ||||||||
Yamamoto/2010 [15] | III | 2001–2005 | Japan | OS | MVP | NR | 146 | 63 | 47.9/52.1 | 41% | 60 | 2D |
IC | 147 | 62 | 42.2/57.8 | 29.3% | ||||||||
PC | 147 | 63 | 48.3/51.7 | 49.7% | ||||||||
Senan/2016 [16] | III | 2008–2012 | USA | OS | PP | 22 | 301 | 59.5 | 100 | 76% | 60–66 | 3D |
EP | 23 | 297 | 58.7 | 100 | 74.3% | |||||||
Govindan/2011 [17] | II | 2005–2008 | USA | OS | PP | 32 | 48 | 65 | 35/65 | 69.8% | 70 | 3D |
PP-Cet | 53 | 66 | 34/66 | 85.4% |